
High-Dose Vitamin C Doubles Pancreatic Cancer Patient Survival Rates: Clinical Trial
By Cara Michelle Miller Adding high-dose vitamin C to a cancer treatment regimen may double survival time, according to a clinical trial that tested this in pancreatic cancer patients. Typically diagnosed in its advanced stages, pancreatic cancer has a poor prognosis and leaves patients with limited treatment options, with most surviving only eight months with standard chemotherapy.
More Stories
D. E. Shaw & Co. Inc. Has $3.50 Million Stake in CSX Co. (NASDAQ:CSX)
D. E. Shaw & Co. Inc. trimmed its stake in CSX Co. (NASDAQ:CSX – Free Report) by 91.6% during the...
Focus Partners Wealth Sells 327,820 Shares of WEX Inc. (NYSE:WEX)
Focus Partners Wealth reduced its stake in WEX Inc. (NYSE:WEX – Free Report) by 98.5% during the fourth quarter, HoldingsChannel.com...
D. E. Shaw & Co. Inc. Takes $3.68 Million Position in Novanta Inc. (NASDAQ:NOVT)
D. E. Shaw & Co. Inc. bought a new stake in shares of Novanta Inc. (NASDAQ:NOVT – Free Report) during...
Deutsche Bank AG Increases Stock Position in Armstrong World Industries, Inc. (NYSE:AWI)
Deutsche Bank AG boosted its holdings in Armstrong World Industries, Inc. (NYSE:AWI – Free Report) by 48.8% during the 4th...
Focus Partners Wealth Grows Position in StoneX Group Inc. (NASDAQ:SNEX)
Focus Partners Wealth lifted its holdings in shares of StoneX Group Inc. (NASDAQ:SNEX – Free Report) by 2.1% during the...
Principal Financial Group, Inc. (NYSE:PFG) Shares Sold by Focus Partners Wealth
Focus Partners Wealth cut its stake in shares of Principal Financial Group, Inc. (NYSE:PFG – Free Report) by 84.1% in...